Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up

Jose-Ezequiel Martin1,∗, Jasper C. Broen2, F. David Carmona1, Maria Teruel1, Carmen P. Simeon3, Madelon C. Vonk2, Ruben van ’t Slot4, Luis Rodriguez-Rodriguez5, Esther Vicente6, Vicente Fonollosa3, Norberto Ortego-Centeno7, Miguel A. González-Gay8, Francisco J. García-Hernández9, Paloma García de la Peña10, Patricia Carreira11, Spanish Scleroderma Group†, Alexandre E. Voskuyl12, Annemie J. Schuerwegh13, Piet L.C.M. van Riel2, Alexander Kreuter14, Torsten Witte15, Gabriella Riemekasten16, Paolo Airo17, Raffaella Scorza18, Claudio Lunardi19, Nicolas Hunzelmann20, Jörg H.W. Distler21, Lorenzo Beretta18, Jacob van Laar22, Meng May Chee23, Jane Worthington24, Ariane Herrick24, Christopher Denton25, Filemon K. Tan26, Frank C. Arnett26, Shervin Assassi26, Carmen Fonseca25, Maureen D. Mayes26, Timothy R.D.J. Radstake2,†, Bobby P.C. Koeleman4,‡ and Javier Martin1, †

1Instituto de Parasitologia y Biomedicina Lopez-Neyra, CSIC, Granada, Spain, 2Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, 3Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, 4Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands, 5Servicio de Reumatología, Hospital Clínico San Carlos, Madrid, Spain, 6Servicio de Reumatología, Hospital La Princesa, Madrid, Spain, 7Servicio de Medicina Interna, Hospital Clínico Universitario, Granada, Spain, 8Servicio de Reumatología, Hospital Marqués de Valdecilla, Santander, Spain, 9Servicio de Medicina Interna, Hospital Virgen del Rocio, Sevilla, Spain, 10Servicio de Reumatología, Hospital Ramón y Cajal, Madrid, Spain, 11Hospital 12 de Octubre, Madrid, Spain, 12VU University Medical Center, Amsterdam, The Netherlands, 13Department of Rheumatology, University of Leiden, Leiden, The Netherlands, 14Department of Dermatology, Josefs-Hospital, Ruhr University Bochum, Bochum, Germany, 15Hannover Medical School, Hannover, Germany, 16Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 17Rheumatology Unit and Chair, Spedali Civili, Università di gli Studi, Brescia, Italy, 18Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale MaRepiore Policlinico and University of Milan, Milan, Italy, 19Department of Medicine, Policlinico GB Rossi, University of Verona, Verona, Italy, 20Department of Dermatology, University of Cologne, Cologne, Germany, 21Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen 91054, Germany, 22Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK, 23Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK, 24Department of Rheumatology and Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, 25Centre for Rheumatology, Royal Free and University College School, London, UK and 26The University of Texas Health Science Center—Houston, Houston, TX, USA

Received November 23, 2011; Revised and Accepted March 5, 2012

∗To whom correspondence should be addressed. Email: cebercoto@ipb.csic.es
†See supplementary note.
‡These authors contributed equally to this work.

© The Author 2012. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Systemic sclerosis (SSc) is a complex autoimmune disease affecting the connective tissue; influenced by genetic and environmental components. Recently, we performed the first successful genome-wide association study (GWAS) of SSc. Here, we perform a large replication study to better dissect the genetic component of SSc. We selected 768 polymorphisms from the previous GWAS and genotyped them in seven replication cohorts from Europe. Overall significance was calculated for replicated significant SNPs by meta-analysis of the replication cohorts and replication-GWAS cohorts (3237 cases and 6097 controls). Six SNPs in regions not previously associated with SSc were selected for validation in another five independent cohorts, up to a total of 5270 SSc patients and 8326 controls. We found evidence for replication and overall genome-wide significance for one novel SSc genetic risk locus: CSK [P-value = 5.04 × 10^{-12}, odds ratio (OR) = 1.20]. Additionally, we found suggestive association in the loci PSD3 (P-value = 3.18 × 10^{-7}, OR = 1.36) and NFKB1 (P-value = 1.03 × 10^{-6}, OR = 1.14). Additionally, we strengthened the evidence for previously confirmed associations. This study significantly increases the number of known putative genetic risk factors for SSc, including the genes CSK, PSD3 and NFKB1, and further confirms six previously described ones.

INTRODUCTION

Systemic sclerosis (scleroderma, SSc) is an autoimmune disease characterized by vascular damage, altered immune responses and extensive fibrosis of skin and internal organs (1), in which common genetic factors play an essential role, similar to most complex autoimmune diseases (2,3). So far, only a limited number of genes explaining little of the genetic variance present have been found in SSc (4,5).

In other autoimmune complex diseases for which extensive follow-up studies have been performed, such as inflammatory bowel disease and systemic lupus erythematosus (SLE), ~90 and 35 associated genes, respectively, have been identified (6,7). Therefore, it is expected that a number of risk factors for SSc are still to be defined. To date, only two genome-wide association studies (GWAS) have been published in populations of European ancestry in SSc (8,9). This calls for further replication studies and meta-analysis of SSc.

Due to the high rate of type 1 errors inherent to the GWAS technique, a number of strategies can be followed to discern truly associated genes from false positives in the tier 2 range of associations (ranging $P$-values from $10^{-7}$ to $5 \times 10^{-8}$), e.g. biological pathway analysis, meta-GWAS analysis or genetic interaction analysis. Another approach is to select the most strongly associated genetic variants from GWAS, where most true associations are harbored, by just accepting a small proportion of false negatives left out of the replication study. In this study, we performed the latter approach.

SSc is a clinically heterogeneous disease with a wide range of clinical manifestations (3); patients can be classified according to the severity of skin or organ involvement of the disease (10), or according to the presence or absence of several highly disease-specific auto-antibodies which are almost mutually exclusive in individual patients (1). Each of these disease phenotypes has proven to have specific genetic associations (11–17). In order to determine more of the genetic component of this profoundly disabling disease, such considerations need to be taken into account when selecting a battery of genetic variants to further test in other populations.

Considering the above, we followed the strategy of replication and validation of 768 genetic associations selected from our previous GWAS of SSc under different criteria in seven independent cohorts of European ancestry from five European countries, and subsequently performed a meta-analysis including a total of 5270 SSc patients and 8326 healthy controls.

RESULTS

After quality filtering the replication stage data, 720 out of the 768 selected SNPs were analyzed. Mantel–Haenszel meta-analysis was performed for the three replication cohorts and for those cohorts together with the four GWAS cohorts. Six SNPs were selected for the validation stage in five independent cohorts. The overall process followed in the present study is summarized in Figure 1.

The genotyping success call rate was 99.88 and 97.99% in the replication and validation stages, respectively. Table 1 shows the statistics for the six SNPs selected for validation, while Table 2 shows previously described associations with SSc. Figure 2 shows meta-analysis association results of GWAS and replication cohorts for all 720 SNPs. Figure 3 shows relative risk for each of the three novel associations found in this study, for each population analyzed separately and for the meta-analysis. Detailed analysis and results for each associated region can be found below.

Novel SSc genetic associations

After the replication stage (genotyping of 768 SNPs selected from GWAS data), six SNPs were selected for validation with GWAS and replication combined Mantel–Haenszel $P$-value ($P_{\text{MH}}$) lower than $1 \times 10^{-5}$ (in either the complete set of patients or its subphenotypes) and located in regions not previously associated with SSc. The SNPs in NFKB1, PSD3, ACADS and CSK were selected for their association with overall SSc, while those in IPO5/FARP1 and ADAMTS17 were selected for their association with the antitopoisomerase autoantibody (ATA)-positive subgroup of patients. Out of the six SNPs, we were able to validate the association in one of them at the GWAS level ($P < 5 \times 10^{-8}$) and in another two at a suggestive level of association ($5 \times 10^{-8} < P < 5 \times 10^{-6}$).

The GWAS level association in the meta-analysis of all 11 analyzed cohorts was observed for single nucleotide
polymorphisms (SNP) rs1378942 located in an intron of the CSK gene in chromosome 15 \( P_{\text{MH}} = 5.04 \times 10^{-12} \), odds ratio \( (OR) = 1.202 \ (1.14 \text{--} 1.27) \) with SSc (Table 1). Furthermore, we observed a suggestive overall level of association in two of the selected SNPs in all GWAS, replication and validation cohorts. One of them was located in the PSD3 gene, rs10096702 \( P_{\text{MH}} = 3.18 \times 10^{-7} \), \( OR = 1.363 \ (1.21 \text{--} 1.54) \], while the other was in the NFKB1 gene, rs1378938 \( P_{\text{MH}} = 1.03 \times 10^{-6} \), \( OR = 1.140 \ (1.08 \text{--} 1.20) \) (Table 1). Interestingly, we were only able to validate associations with the overall disease, but none of the subphenotype specific ones.

**Previously reported SSc genetic associations**

Associations with SSc previously reported were found for STAT4 (rs10168266, \( P_{\text{MH}} = 1.81 \times 10^{-7} \), \( OR = 1.234 \)), CD247 (rs2056626, \( P_{\text{MH}} = 1.14 \times 10^{-8} \), \( OR = 0.832 \)), TNFSF4 (rs4916334, \( P_{\text{MH}} = 1.00 \times 10^{-5} \), \( OR = 1.861 \)), TNFAIP3 (rs2220926, \( P_{\text{MH}} = 2.29 \times 10^{-6} \), \( OR = 1.463 \)) and TNPO3/IRF5 (rs4728142, \( P_{\text{MH}} = 4.74 \times 10^{-10} \), \( OR = 1.216 \)) and rs10488631, \( P_{\text{MH}} = 1.58 \times 10^{-18} \), \( OR = 1.513 \), further confirming their role in SSc (Table 2). Since several SNPs within both TNPO3/IRF5 and IRF8 genomic regions were selected, a conditional logistic regression analysis was performed to determine the independent signals of both loci (Table 3). While these associations found within each previously reported region spanned across the whole disease, SNP rs11642873 in IRF8 was significantly associated with lcSSc \( P_{\text{MH}} = 2.30 \times 10^{-9} \), \( OR = 0.730 \) and only marginally with dcSSc \( P_{\text{MH}} = 3.77 \times 10^{-2} \), \( OR = 0.874 \).

**DISCUSSION**

Through a large replication study, designed using previously published GWAS data, we have been able to identify novel genetic associations with SSc (Table 1), and to provide further evidence for previously reported associations (Table 2). In the present study, a genetic variant within the CSK region, selected for replication because it was associated with SSc in the US cohort, has been identified as susceptibility factor for this disease. Furthermore, two other suggestive associations have been found in PSD3 and NFKB1 genetic variants, which were included in this study because they reached statistical significance in the European cohort. Further investigation will be required to further clarify the potential role of these two signals in SSc genetic predisposition.

CSK (c-src tyrosine kinase) is known to phosphorylate a tyrosine at the C-terminus of src kinases leading to their inactivation \( (18,19) \). In turn, src kinases are involved in fibrosis through their regulation of FAK \( (19,20) \), which is necessary for transmission of integrin signaling upon adhesion of fibroblasts to the extracellular matrix [and thus, their differentiation into myofibroblasts \( (21) \)] and has been involved in experimental pulmonary fibrosis \( (20) \), a major hallmark of SSc. Indeed, it has been demonstrated that either incubation of fibroblasts with Csk inhibitors or overexpression of Csk lead to a decreased expression of COLIA1, COLIA2 and FNI, which are key components of the fibrotic process \( (22) \). Thus, genetics variants in CSK can be affecting its expression or functionality in a way that src kinases are not inhibited, which in turn will contribute to the fibrosis in SSc. Furthermore, the CSK variant rs1378938, which is in relatively high linkage disequilibrium (LD) with the SSc-associated rs1378942 reported here \( (n^2 = 0.72 \text{ in the CEU population of the HapMap project, has been recently associated with celiac disease } (23) \). Consequently, it is likely that CSK may represent another common autoimmunity risk factor. Further studies in related autoimmune disorders, such as SLE and rheumatoid arthritis (RA), may be performed to draw firm conclusions about this hypothesis.

NFKB has been extensively described to participate in and control the inflammatory process and thus, its role in the development of autoinflammatory disorders is widely accepted \( (24,25) \). The gene NFKB1 (nuclear factor of kappa light polypeptide gene enhancer in B-cell 1) encodes a 105 kDa protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kDa protein. The 105 kDa protein is a Rel protein-specific transcription inhibitor and the 50 kDa protein is a DNA-binding subunit of the NFκB protein complex. SNP rs1598859, located in an intron of NFKB1, has been identified in this study as a risk genetic factor for SSc. This variant, or any other in the same haplotype block, could be affecting the expression or the function of NFKB1, altering the inflammatory response, and thus participating in the development and course of the disease. Indeed, an ATTG in/del in the promoter of NFKB1 has been recently...
Table 1. Novel genetic associations found in this study with SSc

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Chr.</th>
<th>Gene</th>
<th>SNP</th>
<th>Base pair&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Location</th>
<th>Change&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Stage</th>
<th>Sample size</th>
<th>MAF</th>
<th>P-value&lt;sup&gt;c&lt;/sup&gt;</th>
<th>OR&lt;sup&gt;d&lt;/sup&gt;</th>
<th>CI (95%)</th>
<th>Breslow–Day P-value&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSc 4q24</td>
<td>NFKB1</td>
<td>rs1598859</td>
<td>103 725 482</td>
<td>Intron C/T</td>
<td>GWAS</td>
<td>2357 5187</td>
<td>0.358 3.12 × 10⁻⁶</td>
<td>1.188</td>
<td>1.11–1.28</td>
<td>0.151</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSc 8p22</td>
<td>PSD3</td>
<td>rs10096702</td>
<td>18 642 877</td>
<td>Intron A/G</td>
<td>GWAS</td>
<td>2357 5187</td>
<td>0.044 1.05 × 10⁻⁵</td>
<td>1.435</td>
<td>1.22–1.69</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSc 12q24</td>
<td>ACADS</td>
<td>rs558275</td>
<td>119 681 274</td>
<td>Intergenic A/G</td>
<td>GWAS</td>
<td>2357 5187</td>
<td>0.398 6.46 × 10⁻⁶</td>
<td>0.848</td>
<td>0.79–0.91</td>
<td>0.457</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATA+ 13q32</td>
<td>IPOS/FARPI</td>
<td>rs586851</td>
<td>97 542 564</td>
<td>Intergenic C/A</td>
<td>GWAS</td>
<td>462 5187</td>
<td>0.103 1.36 × 10⁻³</td>
<td>1.391</td>
<td>1.14–1.70</td>
<td>0.086</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSc 15q24</td>
<td>CSK</td>
<td>rs1378942</td>
<td>72 864 420</td>
<td>Intron C/A</td>
<td>GWAS</td>
<td>2357 5187</td>
<td>0.362 7.19 × 10⁻⁷</td>
<td>1.199</td>
<td>1.12–1.29</td>
<td>0.573</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATA+ 15q26</td>
<td>ADAMTS17</td>
<td>rs2289584</td>
<td>98 707 019</td>
<td>Intergenic T/G</td>
<td>GWAS</td>
<td>462 5187</td>
<td>0.175 9.04 × 10⁻⁵</td>
<td>1.391</td>
<td>1.18–1.64</td>
<td>0.383</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Chr., chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence intervals. GWAS, genome-wide association study; Rep, replication stage (768 SNPs); Val, validation stage (6 SNPs).

<sup>a</sup>All genomic positions are referent to genome build 36.

<sup>b</sup>Minor allele first.

<sup>c</sup>Mantel–Haenszel meta-analysis of the cohorts involved in the corresponding stage of the analysis (see Materials and Methods).

<sup>d</sup>All ORs are for the minor allele.
<table>
<thead>
<tr>
<th>Chr.</th>
<th>Gene</th>
<th>SNP</th>
<th>Base pair*</th>
<th>Location</th>
<th>Changeb</th>
<th>Sample size</th>
<th>MAF</th>
<th>P-valuec</th>
<th>ORd</th>
<th>CI (95%)</th>
<th>Breslow–Day P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1q24</td>
<td>CD247</td>
<td>rs2056626</td>
<td>165 687 049</td>
<td>Intron</td>
<td>G/T</td>
<td>3237 6097</td>
<td>0.396</td>
<td>1.14 x 10^-8</td>
<td>0.832</td>
<td>0.78–0.89</td>
<td>5.14 x 10^-1</td>
</tr>
<tr>
<td>1q25</td>
<td>TNFSF4</td>
<td>rs10798269</td>
<td>171 576 336</td>
<td>Intergenic</td>
<td>A/G</td>
<td>3237 6097</td>
<td>0.336</td>
<td>1.29 x 10^-5</td>
<td>0.864</td>
<td>0.81–0.92</td>
<td>7.78 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs4916334</td>
<td>171 600 452</td>
<td>Intergenic</td>
<td>G/T</td>
<td>3237 6097</td>
<td>0.334</td>
<td>1.00 x 10^-5</td>
<td>0.861</td>
<td>0.81–0.92</td>
<td>8.18 x 10^-1</td>
</tr>
<tr>
<td>2q32</td>
<td>STAT4</td>
<td>rs10168266</td>
<td>191 644 049</td>
<td>Intron</td>
<td>T/C</td>
<td>2372 4395</td>
<td>0.214</td>
<td>1.81 x 10^-7</td>
<td>1.234</td>
<td>1.14–1.34</td>
<td>1.11 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs4728142</td>
<td>128 361 203</td>
<td>Intergenic</td>
<td>A/G</td>
<td>3237 6097</td>
<td>0.463</td>
<td>4.74 x 10^-10</td>
<td>1.216</td>
<td>1.14–1.29</td>
<td>9.12 x 10^-2</td>
</tr>
<tr>
<td>6q23</td>
<td>TNFAIP3</td>
<td>rs2230926</td>
<td>138 237 759</td>
<td>Exon</td>
<td>G/T</td>
<td>3237 6097</td>
<td>0.036</td>
<td>2.29 x 10^-6</td>
<td>1.463</td>
<td>1.25–1.71</td>
<td>4.80 x 10^-2</td>
</tr>
<tr>
<td>7q32</td>
<td>TNPO3/IRF5</td>
<td>rs10488631</td>
<td>128 381 419</td>
<td>Intergenic</td>
<td>C/T</td>
<td>3237 6097</td>
<td>0.116</td>
<td>1.58 x 10^-18</td>
<td>1.513</td>
<td>1.38–1.66</td>
<td>6.94 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs12531711</td>
<td>128 404 702</td>
<td>Intergenic</td>
<td>G/A</td>
<td>3237 6097</td>
<td>0.115</td>
<td>3.31 x 10^-19</td>
<td>1.527</td>
<td>1.39–1.68</td>
<td>7.11 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs12537284</td>
<td>128 505 142</td>
<td>Intergenic</td>
<td>A/G</td>
<td>3237 6097</td>
<td>0.141</td>
<td>1.85 x 10^-9</td>
<td>1.301</td>
<td>1.19–1.42</td>
<td>8.77 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2084654</td>
<td>128 516 364</td>
<td>Intergenic</td>
<td>G/A</td>
<td>3237 6097</td>
<td>0.339</td>
<td>1.64 x 10^-6</td>
<td>1.711</td>
<td>1.10–1.25</td>
<td>2.58 x 10^-1</td>
</tr>
<tr>
<td>16q24</td>
<td>IRF8</td>
<td>rs11117425</td>
<td>84 529 772</td>
<td>Intergenic</td>
<td>T/C</td>
<td>3237 6097</td>
<td>0.296</td>
<td>1.43 x 10^-6</td>
<td>0.845</td>
<td>0.79–0.91</td>
<td>1.96 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs11644034</td>
<td>84 530 113</td>
<td>Intergenic</td>
<td>A/G</td>
<td>3237 6097</td>
<td>0.196</td>
<td>8.89 x 10^-8</td>
<td>0.804</td>
<td>0.74–0.87</td>
<td>4.03 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs12711490</td>
<td>84 530 529</td>
<td>Intergenic</td>
<td>C/T</td>
<td>3237 6097</td>
<td>0.196</td>
<td>6.43 x 10^-8</td>
<td>0.802</td>
<td>0.74–0.87</td>
<td>3.56 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7202472</td>
<td>84 535 003</td>
<td>Intergenic</td>
<td>T/G</td>
<td>3237 6097</td>
<td>0.182</td>
<td>1.58 x 10^-7</td>
<td>0.802</td>
<td>0.74–0.87</td>
<td>3.65 x 10^-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs11642873</td>
<td>84 549 206</td>
<td>Intergenic</td>
<td>C/A</td>
<td>3237 6097</td>
<td>0.176</td>
<td>2.30 x 10^-9</td>
<td>0.730</td>
<td>0.72–0.86</td>
<td>8.28 x 10^-1</td>
</tr>
</tbody>
</table>

Chr., chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence intervals.

*All genomic positions are referent to genome build 36.

*Minor allele first.

*Mantel–Haenszel meta-analysis of GWAS and GoldenGate cohorts.

*All ORs are for the minor allele.

*TAD4 SNP rs10168266 was not genotyped in the European GWAS cohorts, nor could its genotype could be imputed.

*RF8 SNP rs11642873 association was confined to lcSSc and these are the statistical shown in the table rather than global SSc as in the rest of the SNPs.
Figure 2. The Manhattan plot of the GWAS and replication cohorts meta-analysis. Grey dots represent $P$-values of SNPs which are genotyped only in the GWAS cohorts in the previous study by Radstake et al. (8). Other color dots represent $P_{MH}$ values of the 720 SNPs which were in both the GWAS and the replication cohorts (Mantel–Haenszel meta-analysis). Gene names in black have been previously reported as genetic risk factors for SSc, while gene names in red are novel ones.
Dieude et al. (29) found the SNP rs5029939 in TNFAIP3 associated with SSc, which showed stronger association in the dcSSc and ATA+ subgroups of the disease, although the association remained significant in the opposing lcSSc and ACA+ subgroups. In the present study, rs2230926 (in total LD with rs5029939 in the HapMap CEU population) has shown GWAS level association with the global SSc, and no sign of heterogeneity in the SSc subgroups was detected (Table 2). Taking both studies together, the association of TNFAIP3 is most likely due to an effect on SSc susceptibility overall rather than any of its sub-phenotypes. The previously reported fluctuating level of significance is probably due to different population composition and cohort size (1656 cases and 1311 controls in the study by Dieude et al. (29) and 3237 cases and 6097 controls in the present study). SNP rs2230926 is located on exon 3 of TNFAIP3, and encodes for a phenylalanine to cysteine change at residue 127 which has been demonstrated to alter the function of the protein, which makes it a functionally associated genetic variant with SLE (35).

Association in the TNPO3/IRF5 region has been detected previously in SSc (8,33,34) and SLE (36,37). The three independently associated polymorphisms have been detected in SLE: an in/del in exon 6 which change the expression level of IRF5 (tagged by rs10488631 in our study), a variant in exon 1B which affects splicing of this exon (not tagged in our study) and a variant which disrupts a polyA signal site (tagged by rs4728142 in our study). Our findings in the present study are consistent with associations found in SLE. We detect two of the three independent variants (Table 3): the in/del and the polyA signal, yet the variant in exon 1B was not captured in this study. This observation adds more evidence for a similar genetic component of SSc and SLE. Nevertheless, further research will be needed in order to determine whether the variant in exon 1B, affecting splicing of the gene, also has a major role in SSc.

IRF8 has been recently described as a risk factor for lcSSc (30) and has also been associated with the risk of multiple sclerosis (38). Of all the SNPs selected for replication in the present study, only rs11642873 remained independently significant (Table 3), and its association was found, as in the previous study, exclusively confined to lcSSc. Further fine-mapping and functional studies are necessary in order to determine the role of genetic variants in IRF8 in the pathogenesis of SSc and autoimmunity.

In summary, by the analysis of 720 genetic variants, selected from GWAS data’s ‘grey zone’ of association, we describe three new genetic risk factors for SSc (CSK, PSD3 and NFKB1) and confirm five previously reported associations (CD247, STAT4, TNFAIP3, TNPO3/IRF5, TNFSF4 and IRF8). Also in the case of TNPO3/IRF5, we clarify the nature of the association with SSc which is similar to that found in SLE, thus highlighting the similarities of the genetic component for both diseases.

MATERIALS AND METHODS

Populations

The four populations used in the previous SSc GWAS have been previously described (8). Replication and validation
cohorts from Spain (two independent cohorts), Germany, Netherlands, Italy (two independent cohorts) and the UK for a total of 2913 cases and 3139 controls were recruited from hospitals and blood banks from each of these countries (numbers before quality control filters). Key features of these populations can be found in Supplementary Material, Table S1. This study was approved by the local ethics committees of the participating hospitals. All of the SSc patients participating in this study met American College of Rheumatology criteria (39) and were classified in the disease groups based on the presence of the two most common autoantibodies (i.e. ACA and ATA) in our selection criteria (1,3,10). Because of the differences between the US and European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples in the 

**Study design**

**SNP selection.** First, we aimed to select the putative SSc-associated genetic variants that did not reach genome-wide significance in our initial GWAS (8). We filtered GWAS data as previously published. We excluded from our analysis the extended HLA region on chromosome six, since association of this region with SS is well known, and was not the focus of the present study. Since there is growing evidence for the existence of genetic heterogeneity in SS, we included the clinical subtypes of the disease (i.e. lcSSc and dcSSc) and the presence of the two most common autoantibodies (i.e. ACA and ATA) in our selection criteria (1,3,10). Because of the differences between the US and European samples in the PCA, we decided to select the SNPs for each set separately, lending greater weight to the European samples (it should be noted that all our replication cohorts were of European countries).

We selected all SNPs with a Mantel–Haenszel, \( \lambda \) corrected \( P \)-value lower than \( 10^{-3} \) from the European cohorts (i.e. Netherlands, Germany and Spain) meta-analysis. We also selected all SNPs with a Mantel–Haenszel \( \lambda \)-corrected \( P \)-value lower than \( 10^{-3} \) in the lcSSc, dcSSc, ACA+ and ATA+ subgroups. We also considered the possibility that SNPs associated in one of the three populations could have been filtered out in the others due to any criteria, so we included all SNPs with a corrected \( P \)-value lower than \( 10^{-4} \) in any of the three populations before merging the data sets. This gave a total of 676 SNPs selected. In order to use all the genotyping capacity of the chosen platform (in which 768 SNPs could be analyzed), and taking into consideration that the first 676 SNPs were selected only from the European panel, we also included the 92 previously non-described independent signals from the US panel that showed the most significant \( P \)-values.

The overall strategy followed in the present study can be found in Figure 1.

**Replication stage.** In this stage, we aimed to confirm selected associations from GWAS data on case/control cohorts from Spain, Holland and Italy up to a total of 880 cases and 910 controls. All individuals in these cohorts were genotyped for the 768 selected SNPs and association analyses were performed.

**Validation stage.** At this point, we selected the top SNPs from the meta-analysis of the pervious stages (those genotyped in
GWAS and GoldenGate platforms) and further tested their association in larger cohorts from Spain, Germany, Italy and the UK up to a total of 2033 cases and 2229 controls. All SNPs with a meta-analysis P-value <1 × 10−5 either in the disease or any of its subphenotypes (i.e. lcSSc, dcSSc, ACA+ or ATA+) and not previously reported to be associated with SSC were selected for validation, comprising a total of six SNPs. Finally, we performed meta-analyses for all associated SNPs combining the GWAS and all replication cohorts.

Genotyping methods

The replication cohort was genotyped for 768 SNPs, selected from the GWAS analysis as described above, using a custom Illumina GoldenGate array run on the Illumina iScan system. The validation stage was genotyped using TaqMan genotyping assays from Applied Biosystems.

Genotype imputation of data

As described in Radstake et al. (8), the different cohorts were genotyped using different genotyping arrays (the European cohorts were genotyped mostly with the Illumina HumanHap 370k array, whereas the US cohort was genotyped with the Illumina 550k array). As a consequence, it was possible that some SNPs were present in one but not in the other platform. To prevent this, a genotype imputation was performed in all the GWAS cohorts to obtain a full overlap between platforms. Imputation was performed with IMPUTE software version 1.00 as previously described (40), using as reference panels the CEU and TSI HapMap populations.

Data analysis

All data were analyzed using Plink software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (41). LD patterns among SNPs were also calculated with the r2 statistic using HaploView software (42). Manhattan plots were generated using HelixTree SNP Variation Suite 7 (http://www.goldenhelix.com/SNP_Variation/HelixTree/index.html). In order to avoid any position discrepancies, all base-pair locations for the analyzed genetic variations correspond to those reported in the genome build 36, as these were the positions used in the original GWAS.

All data were quality filtered using the following criteria: Hardy–Weinberg equilibrium P-value > 0.001 on controls of any of the populations analyzed separately, minor allele frequency > 0.01, success call rate per individual > 0.95 and per SNP > 0.95. After applying quality control, remaining SNPs were statistically analyzed using the Chi-squared case/control approach in 1433 cases and 1644 controls. The meta-analysis of the different cohorts was conducted using the Mantel–Haenszel test to calculate a pooled OR, and the 95% confidence interval for the OR was estimated using a random effect model. Heterogeneity between cohorts was tested using the Breslow–Day test (P-values <0.05 were considered statistically significant); nevertheless, we did not rule out any association in the basis of OR heterogeneity. Combined P-values for the Mantel–Haenszel tests were calculated as implemented in Plink. The independence of effects of SNPs in the same genetic region was tested by multiple logistic regression analysis, conditioning each SNP to all others, as implemented in the Plink software. Population stratification was assessed by PCA as previously described (43). All individuals who deviated more than four standard deviations from the centroid of their population were removed as outliers.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We thank Sofia Vargas, Sonia Garcia and Gema Robledo for their excellent technical assistance, and all the patients and healthy controls for kindly accepting their essential collaboration. We would also like to thank the following organizations: the EULAR Scleroderma Trials and Research (EUSTAR), the German Network of Systemic Sclerosis and Banco Nacional de ADN (University of Salamanca, Spain).

FUNDING

This work was supported by the following grants: J.M. was funded by GEN-FER from the Spanish Society of Rheumatology, SAF2009-11110 from the Spanish Ministry of Science, CTS-4977 from Junta de Andalucía (Spain), Redes Temáticas de Investigación Cooperativa Sanitaria Program, RD08/0075 (RIER) from Instituto de Salud Carlos III (ISCIII, Spain) and Fondo Europeo de Desarrollo Regional (FEDER). T.R.D.J.R. was funded by the VIDI laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation (National Reumafonds). J.M. and T.R.D.J.R. were sponsored by the Orphan Disease Program grant from the European League Against Rheumatism (EULAR). B.P.C.K. is supported by the Dutch Diabetes Research Foundation (grant 2008.40.001) and the Dutch Arthritis Foundation (Reumafonds, grant NR 09-1-408). T.W. is supported by the grant DFG WI 1031/6-1 and by the grant DFG WI 1031/6-1. N.O.-C. was funded by PI-0590-2010, Consejería de Salud, Junta de Andalucía, Spain. F.K.T., F.C.A. and M.D.M. were supported by NIH Scleroderma Family Registry and DNA Repository (N01-AR-0-2251), NIH RO1- AR055258 and NIH Center of Research Translation in Scleroderma (1P50AR054144), and the Department of Defense Congresionally Directed Medical Research Programs (W81XWH-07-01-0111). C.F. was supported by ‘The Raynaud’s and Scleroderma Association’ and ‘The Scleroderma Society’.

REFERENCES


